[The prognostic value of selected immunological factors in ovarian cancer patients]
- PMID: 27162313
[The prognostic value of selected immunological factors in ovarian cancer patients]
Abstract
Ovarian cancer is the most aggressive gynecological cancer and is often diagnosed in advanced stage. Constantly we are looking for new prognostic factors which would enable early diagnosis, increase the effectiveness of therapeutic intervention. There is to little data about immunological predictors in ovarian cancer. The tumor's microenvironment is designated by regulatory T cells, cytotoxic T cells, dendritic cells (DCs), tumor - associated macrophages (TAMs), monocytes, plasma cells and cytokines, such as IL-6, IL-8, IL-10, IL-17 and TGF-beta. Some of them are responsible for the inhibition and others induce tumor growth. Ovarian cancer patients with high ratio of CD8 + TILs to Treg present longer overall survival time (OS). The presence of T helper cells in ascites is associated with longer OS. Furthermore, patients with a lower rate plasmocytoid DCs infiltrating tumor tissue demonstrate longer progression-free survival time (PFS). Women with increased M1/M2 ratio present higher five-year survival rate. The presence of immunologically competent cells and secreted cytokines give motivation to evaluate their prognostic value. Perhaps this strategy will contribute to longer progression-free survival time and overall survival time in those patients.
Similar articles
-
Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.Gynecol Oncol. 2017 Oct;147(1):181-187. doi: 10.1016/j.ygyno.2017.07.007. Epub 2017 Jul 8. Gynecol Oncol. 2017. PMID: 28698008
-
Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients.Sci Rep. 2020 Apr 8;10(1):6096. doi: 10.1038/s41598-020-63276-1. Sci Rep. 2020. PMID: 32269279 Free PMC article.
-
Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.Gynecol Oncol. 2008 Feb;108(2):421-7. doi: 10.1016/j.ygyno.2007.10.018. Epub 2007 Nov 26. Gynecol Oncol. 2008. PMID: 18036640
-
IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-γ.Immunotherapy. 2011 Apr;3(4 Suppl):23-6. doi: 10.2217/imt.11.30. Immunotherapy. 2011. PMID: 21524164 Review.
-
Ovarian cancer biology and immunotherapy.Int Rev Immunol. 2014 Oct;33(5):428-40. doi: 10.3109/08830185.2014.921161. Epub 2014 Jun 9. Int Rev Immunol. 2014. PMID: 24911597 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials